SP
Our Partners
A pharmaceutical market built on trust.
We treat our partners as family. We work very closely together on a daily basis — on dossiers, on launches, on the quality of every batch that reaches a pharmacy. Each name below is a manufacturer we have audited, contracted, and integrated into our cold-chain.
- Manufacturers
- 12
- Countries
- 6 across Europe
- Categories
- Vitamins, nutraceuticals, functional health
- Standard
- EU GDP, audited annually
Manufacturing partners
Twelve partners. Six countries. One distribution discipline.
VI
Vem İlaç
BF
Biofarm
OM
Omisan Farmaceutici
AF
Aflofarm
SJ
SJA Pharma
ND
NewFaDem
BN
Bionika
MD
Medicair
AB
Antibiotic
VX
Vianex
PF
PharmaZac
What partnership looks like
What we commit to every manufacturer we sign.
Distribution is the visible part. Underneath, partnership is built on dossiers, audits, and the kind of routine collaboration that doesn't show on a website.
Regulatory representation
We act as your local Regulatory Affairs office — dossier preparation, registration, post-market reporting, pharmacovigilance, market-authorisation renewal.
Cold-chain custody
Audited warehousing in the 2–25°C range, continuous temperature monitoring, and end-to-end traceability on every shipment your product appears in.
Field marketing
A medical field team visits prescribers across approximately twenty specialties. Your product is introduced in person, with sample management and adverse-event reporting attached.
Quality assurance
We hold to EU GDP. Our auditing schedule runs annually, with internal reviews quarterly. Audit reports are shared with any partner that asks.
Daily collaboration
We work very closely with our partners on a daily basis — on forecasts, on stock, on the small queries that keep a launch on track.
Portfolio curation
Your product enters a portfolio that is therapeutically coherent. We do not stock everything — we stock the lines our prescriber network is asking for.
Considering Biomarmedical as your regional distributor?
We will review your dossier, share our reference letters, and propose a launch plan within ten working days of an introduction call.
